2 terminated, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Foghorn Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC FHD-286 - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-04 | 2026-04-27 |
| FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia Decitabine, Venetoclax, FHD-286 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | Montefiore Medical Center | 33 | 2026-02-03 | 2026-03-03 |
| FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors FHD-609 - Advanced Synovial Sarcoma | Phase 1 | Terminated | Foghorn Therapeutics Inc. | 55 | 2021-08-17 | 2025-03-04 |
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies FHD-286, Low Dose Cytarabine, Decitabine - Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia | Phase 1 | Active not recruiting | Foghorn Therapeutics Inc. | 144 | 2021-06-14 | 2025-07-10 |
| FHD-286 in Subjects With Metastatic Uveal Melanoma FHD-286 - Metastatic Uveal Melanoma | Phase 1 | Terminated | Foghorn Therapeutics Inc. | 76 | 2021-05-11 | 2024-04-25 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Leukemia, Myelomonocytic, Chronic (1) · Rhabdoid Tumor (1) · Sarcoma (1) · Sarcoma, Synovial (1) · Small Cell Lung Carcinoma (1) · Uveal Melanoma (1)
Decitabine (2) · Cytarabine (1) · venetoclax (1)
United States (5) · France (2) · Italy (1) · Netherlands (1) · Spain (1)
Sarah Reilly, MD (3) · Jacob Sands (1) · Mendel R Goldfinger, MD (1)
2025 (1)